Skip to the page

Data / Federal rules / 2024-08262

340B Drug Pricing Program; Administrative Dispute Resolution Regulation

The Health and Human Services Department published this final rule in the Federal Register on April 19, 2024. It took effect on June 18, 2024.

SpecStream is the live web data engine for teams and agents. It reads every rule and proposed rule in the Federal Register each morning, and this page is that reading. Name your industry once and new rules, comment deadlines and effective dates arrive in your sheet, CRM, Slack or agent as they are published.

What the agency says

The Health Resources and Services Administration administers section 340B of the Public Health Service (PHS) Act, which is referred to as the "340B Drug Pricing Program" or the "340B Program." This final rule will apply to all drug manufacturers and covered entities that participate in the 340B Program. The final rule sets forth the requirements and procedures for the 340B Program's administrative dispute resolution (ADR) process. This final rule revises the 340B administrative dispute resolution process set forth in the Code of Federal Regulations.

Key facts

Document number
2024-08262
Type
Final rule
Action
Final rule
Agency
Health and Human Services Department
Published
April 19, 2024
Takes effect
June 18, 2024
Dates
This final rule is effective June 18, 2024.
Docket
Docket No. 2021-0004
Regulation ID (RIN)
0906-AB28
Code of Federal Regulations
42 CFR 10
Topics
Biologics; Business and industry; Diseases; Drugs; Health; Health care; Health facilities; Hospitals
Significant
Yes, under Executive Order 12866
Pages
17

The document on federalregister.gov PDF

Other documents from the Health and Human Services Department

Everything from the Health and Human Services Department · Rules on biologics · Rules on business and industry · Rules on diseases · Published in April 2024

Read from the Federal Register API, last updated 2026-10-23. The document on federalregister.gov is the official record; dates and dockets can change through later corrections. Free to reuse with credit to SpecStream under CC BY 4.0.